Co-Authors
This is a "connection" page, showing publications co-authored by Alessandro Armuzzi and Daniela Pugliese.
Connection Strength
1.680
-
The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When "non-urgent" does not mean "deferrable". Dig Liver Dis. 2020 11; 52(11):1238-1240.
Score: 0.888
-
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy. Aliment Pharmacol Ther. 2021 03; 53(6):764-765.
Score: 0.233
-
The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. Inflamm Bowel Dis. 2020 08 20; 26(9):1306-1314.
Score: 0.225
-
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. United European Gastroenterol J. 2020 08; 8(7):775-781.
Score: 0.221
-
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. Inflamm Bowel Dis. 2020 10 23; 26(11):e134-e136.
Score: 0.057
-
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. United European Gastroenterol J. 2020 12; 8(10):1228-1235.
Score: 0.057